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ABSTRACT
Gene therapy has to date gained immense interest as a potential method for treating genetic
disorders such as Parkinson’s and cystic fibrosis. The liver being a central organ of metabolism
is susceptible to several metabolic disorders which could be targeted through liver directed
gene delivery. The most common diseases being viral hepatitis and hepatocellular carcinoma
towards which this study is focused. Non-viral vectors have gained wide interest as the vector
of choice for delivering genes to organs such as the liver, because of their large-scale
production potential, easy preparation, low cost and are relatively non-immunogenic to target
cells / organs.
This study utilized non-viral cationic liposomes targeted to hepatocytes via ligand-receptor
recognition. A total of six cationic liposomes (targeted acetylated /non-acetylated, nontargeted,
pegylated, non-pegylated) were prepared according to the lipid film hydration method. The
liposomes and liposome:DNA complexes were characterized using transmission electron
microscope (TEM) and Zeta sizing to determine morphology, lamellarity and size. Results
showed spherical, unilamellar cationic liposomes and lipoplexes in the size range of 50-200
nm in diameter. Band shift assays showed that these liposomes have strong DNA binding
capabilities which was further confirmed by the ethidium bromide intercalation assays.
Nuclease protection assays showed that liposomes were able to protect the integrity of the DNA
cargo. From the MTT cell viability assays, low cytotoxicity was observed for all liposomes
with cell survival as high as 80 % in most cases. Higher transfection activities were noted in
the hepatocellular carcinoma receptor positive cell line (HepG2), for targeted non-acetylated
liposomes, compared to the acetylated liposomes. The ligand competition assay and the use of
the human embryonic kidney receptor negative cell line (HEK293) confirmed that the
complexes entered the cells via receptor mediated endocytosis. Furthermore, it was confirmed
that the acetylation of the galactose ligands hindered the process of receptor mediation.
Overall, these liposomal formulations are serum tolerant, have low cytotoxicity and are able to
selectively target and transfect hepatocytes in vitro. Hence, they have the potential as future
non-viral gene delivery vehicles and with further optimisation can be tested in vivo.
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1. INTRODUCTION / LITERATURE REVIEW
1.1 GENE THERAPY
Gene therapy entails the delivery of functional genes to target cells in whole organisms, in
order to correct genetic mistakes or to provide the cells with a new functional gene (Khalil et
al., 2006). There are several methods of achieving corrections in the patient cells. One way is
by targeting genes through homologous recombination and the other is by adding a therapeutic
gene, a process known as augmentation. Different levels of gene therapy have been reported
to date. Germline gene therapy, involves correcting the genetic disorders through direct
manipulation of germline cells (Katragadda et al., 2010). In this method, the offspring will
carry the corrected genotype. Ethical, legal and moral reasons have prevented the application
of this technology in human subjects. Transgenic techniques have been used on other species
viz.  delivery of genes from somatic cells to the nuclei of germ cells, during metaphase stage;
ex vivo alteration of egg cells following in vitro fertilization, and manipulation of mouse
embryonic stem cells during in vitro culture using different gene delivery systems.
A second level of gene therapy is somatic gene therapy, where genes are inserted into diploid
cells, and the genetic material not carried through to it progeny cells (Khalil et al., 2006). This
is a safer method since it only affects the target cells. Future offsprings of the targeted
individual are not affected in this method. A significant problem associated with this method
is that it cannot be used for long term expression because the somatic cells in the tissues die
and are ultimately replaced by new cells. Also gene transportation is a limiting factor in this
method. However, it is still used to treat various disorders e.g. psoriasis (Zibert et al., 2011).
Somatic gene therapy can be differentiated into three delivery techniques; ex vivo, in situ and
in vitro. In ex vivo delivery, genetic material is first taken from the target tissue or bone
marrow, manipulated in vitro, and then used to transfect the target cell or tissue. This type of
somatic gene therapy is not immunogenic to target tissues (Katragadda et al., 2010).
However, there are limitations associated with this type of delivery; one being the small
number of cells taken from the target tissue that remain viable. In in situ delivery, genetic
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material is administered directly into the target tissue. This delivery method has been employed
for the delivery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene using
lipid and adenoviral vectors. This gene is delivered directly to a target specific site in the
respiratory tract for the treatment of cystic fibrosis. This delivery method however suffers from
low transfection efficiency. In vivo delivery uses a vector that carries a recombinant gene or
DNA to the target site (Katragadda et al., 2010). This type of delivery has gained much support
as being a useful method of delivery. A limitation associated with this method could be the
inadequate targeting of vectors to the correct tissue sites, although ligands are continually being
developed to improve the targeting efficiencies of vectors used in gene/ drug delivery.
For successful gene therapy, therapeutic genes must be safely and successfully delivered to
targeted cells or tissues and must be efficiently expressed at therapeutical levels. Over the past
20 years, gene therapy has gained wide interest as a method for treating diseases.   It is a
potential method for treating monogenic disorders such as Parkinson’s disease and cystic
fibrosis. It also serves as an alternative technique to traditional chemotherapy methods which
are used to treat various types of cancer (Mintzer and Simanek, 2009). Gene therapy is
considered as a potential medical revolution, although there are still associated obstacles that
need to be overcome. One of the obstacles faced is the complexity of the biological system.
Rapid developments in gene therapy are as a result of a growing understanding of the
molecular mechanisms that define the development of corrective gene delivery systems. These
two areas are important in gene delivery. The systemic gene delivery systems are important
for therapeutic use to cells which cannot be accessed using percutaneous injection. It is also
important in addressing metastatic manifestations which may be located elsewhere in the body.
The therapeutic genes are usually contained in plasmids. When used to replace non-functioning
genes, it offers more understanding on the physiological function of genes. Delivery is effected
using vectors which protect nucleic acid material to be transferred (Katragadda et al., 2010).
1.2 GENE DELIVERY VECTORS
A good plasmid DNA vector should be able to replicate autonomously, be easy to isolate and
purify, be easily introduced into the targeted cells, have suitable marker genes present, and
have unique target sites for various restriction enzymes so gene inserts can be integrated into
3
it. For expression of the inserted gene, the plasmid should have the appropriate promoters and
operators. Since direct naked DNA delivery is inefficient due to biological barriers, gene
carriers which protect the DNA from being degraded by enzymes have been advanced.  This
has led to development of two diverse methods of delivering genes to cells or tissues, viz. i)
the non-viral method and ii) the viral method. Both methods ensure increased transfection
efficiency as shown in Figure 1.1(Katragadda et al., 2010).
Figure 1.1: Different types of gene delivery vectors: Adapted from
http://www.nature.com/gt/journal/v13/n9/figtab/3302692f1.html [accessed 10 October 2013].
1.2.1 VIRAL METHODS
Viral vectors have all the requisites which offer efficient binding to target cells, easy
internalisation and uptake into nucleus where the DNA is released. Viral vectors are often
associated with toxicity and immunogenicity, and hence may be potentially harmful to targeted
cells or tissue. They are also limited with respect to scale-up procedures. Viral vectors include
retroviruses, lentiviruses, adenoviruses, herpes viruses and the adeno-associated viruses. These
viral vectors have different properties which are essential for the delivery of the genes or
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molecules to the target cells or organs. Both the advantages and disadvantages need to be
looked at before considering a specific viral vector/s for gene delivery. Table 1.1 summarizes
the different viral vectors which are currently studied and employed in gene therapy
(Katragadda et al., 2010).
Table 1.1: Comparison of different viral systems.
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1.2.2 NON -VIRAL METHODS
Most non-viral transfer methods allow for targeting strategies and permit targeting of genes to
specific cells. Research endeavours to improve this approach are ongoing as many problems
have arisen over the years. In some cases, there has been expression of undesired proteins
which are harmful to patients, and also down-regulation of gene expression leading to tumours.
(Katragadda et al., 2010). Generally, non-viral vectors compact DNA for delivery, but
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transfection efficiency remains lower than that of viral methods due to the many cellular
barriers and immune defences that must be overcome. Non-viral vectors are biocompatible and
have a large-scale production potential, enabling them to be widely used in the laboratory.  In
in vivo studies, free DNA is degraded by serum nucleases in the blood when injected
intravenously.  Due to this, most research has been engaged in designing cationic compounds
that will form protective complexes with DNA. These compounds have been designed to be
able to avoid gene delivery barriers (Mintzer and Simanek, 2009). Examples include: (i)
Cationic lipids, (ii) Cationic polymers, (iii) Gold nanoparticles, (iv) Magnetic nanoparticles,
(v) Quantum dots, (vi) Silica nanoparticles, (vii) Fullerenes, (viii) carbon nanotubes (CNTs),
and (ix) Supramolecular systems.
(i) Cationic lipids are amphiphilic systems containing a cationic head group
attached by a linker to a hydrophobic lipid moiety. The head group is positively
charged and binds the nucleic acid phosphate groups. They can also be grouped
into various subgroups according to their basic structural characteristics (Liu et
al., 2003). There are monovalent aliphatic lipids which have a single amine
function in their head group, e.g. N[1-(2,3 dioleyloxy) propyl]-N,N,N-
trimethylammonium chloride (DOTMA), 1,2-dioleyl- 3
trimethylammoniumpropane (DOTAP), and N-(2-hydroxyethyl)-N,N-
dimethyl 2,3-bis(tetradecycloxy-1-propanaminium bromide (DMRIE). There
are also multivalent aliphatic lipids which have polar head groups with several
amine functions such as the spermine group, e.g. dioctadecylamido-
glycylspermine (DOGS) (Wasungu and Hoekstra, 2006).
Cationic lipids have a polar head group, which compacts DNA, a lipidic chain,
for self-association through hydrophilic interaction forming micelles or
liposomes; and a linker, that interconnects the two. A lipoplex is a complex
formed by interaction of the cationic lipids and DNA, and resembles a
multilayered structure with compacted DNA (Xun et al., 2014).
(ii) Cationic polymers can be classified into two main groups. The first group are
natural polymers e.g. proteins, peptides and polysaccharides, and the second
group are synthetic polymers e.g. polyethyleneimine (PEI), dendrimers, and
polyphosphoesters (Mintzer and Simanek, 2009). Cationic polymers interact
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with DNA by means of electrostatic interactions, due to the positively charged
amine and ammonium functions. The N/P ratio is a ratio of the number of amine
groups found in the vector versus the number of phosphates in the DNA. This
ratio controls the structure and size of the complex formed between the DNA
and the cationic polymers (Mintzer and Simanek, 2009).
Chitosan is a natural polymer which due to its non-toxic nature is favoured for
both in vitro and in vivo studies. However, it has shown low delivery efficiency
in some cell lines (Liu et al., 2003). It complexes with DNA and has been
widely employed in oral and nasal therapy since it is mucoadhesive. Novel
chitosan derivatives such as aminoethyl- chitin and thiolated- chitosan have
now been employed to improve the transfection efficiency. Intracellular
barriers have been recently avoided by conjugating chitosan to folic acid, so
that folate receptor mediated endocytosis can occur. PEI is another polycation
commonly employed in gene delivery (Liu et al., 2003), however it has shown
higher cytotoxicity than other polymers in vitro.
(iii) Gold nanoparticles: Gold is an inert metal which is not oxidized at lower
temperatures, especially temperatures below its melting point. It does not
interact with atmospheric oxygen and most other chemicals. Hence, these
properties enable gold to be easily manipulated in the presence of atmospheric
conditions (Mintzer and Simanek, 2009).  Since gold nanoparticles can be
synthesized by citrate reduction in an aqueous solution, nanoparticle sizes can
be tuned reliably and routinely from 1 nm to 200 nm (Katragadda et al., 2010).
(iv) Magnetic Nanoparticles: Recently, much attention has been focussed on
developing the nanoparticles. These are metallic clusters which have a good
drug delivery and gene therapy potential. They are able to carry large amounts
of DNA into targeted cells (Katragadda et al., 2010).
(v) Quantum Dots: These are semi-conduction nanomaterials which present bright
fluorescence, narrow emission, broad UV excitation, and high photostability.
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These offer various advantages compared to normally employed organic dyes
and are useful for imaging and sensing (Katragadda et al., 2010).
(vi) Silica Nanoparticles: Silica is a major component of most natural materials
including glass and sand. It is employed in biomedicine due to its ability to be
functionalised.  In gene delivery, the surface of the silica nanoparticles is often
functionalized with amino-silicanes (Katragadda et al., 2010).
(vii) Fullerenes are water-insoluble carbon molecules. Fullerenes have been
functionalized by Nakamura et al (2000) with two diamine side chains. It has
shown transfection efficiency comparable to that of commercially available
reagents. Complexes formed between fullerenes and DNA are usually absorbed
by cells via phagocytosis.
(viii) Carbon nanotubes (CNTs) are cylindrical fullerenes.  CNTs have been
functionalized with an amino-terminal oligoethylene glycol chain. These
complexes associate with DNA and have high delivery efficiencies and low
cytotoxicity.
(ix) Supramolecular systems: It has been shown that highly saccharide-
functionalized porphyrin and calix resorcarene derivatives have high specificity
toward hepatic cells. These derivatives combine with plasmid DNA to form
glycoviruses, which transfect HeLa cells with high efficiency. Series of
calix[n]arenes have been functionalized with guanidinium groups 59, 60 and
alkyl chains which resulted in condensation of DNA and high transfection
(Katragadda et al., 2010).
There are other non-viral methods which can be employed to transfect cells / deliver genes
during gene therapy. These include the physical methods which allow for direct transfer of
naked DNA or nucleic acids into the cytoplasm without using any foreign substance such as
lipids. One such example is the method of microinjection. Microinjection is normally used for
single cell manipulations. Nucleic acids are injected to cells such as oocytes using a
micromanipulator and a microscope. This technique provides various advantages such as high
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transfection efficiency but larger number of cells cannot be transfected using this method
(Katragadda et al., 2010).
Another physical method is the biolistic particle delivery (BPD) where nucleic acids are
delivered into cultured cells. This method can be used to transfect cells in vivo and is only
employed for vaccination and agriculture purposes. BPD is fast, simple and can be used to
transfect both dividing and non-dividing cells but it has a high mortality rate and therefore
requires a large number of cells. A third physical method is electroporation which is a
frequently used technique because it can transfect large DNA fragments with good efficiencies,
however this technique leads to high mortality rates in animals.
1.2.2.1 LIPOSOMES
Liposomes, the basic structure of which can be seen in Figure 1.2, are one of the most widely
employed non-viral vectors in gene therapy. There are different biological properties (Table
1.2) and applications of liposomes in science (Table 1.3), which have been studied recently
and has led to scientists conducting more research on these carrier vectors.




Table 1.2: Biological properties of liposomes.
PROPERTIES EXPLANATION
Biocompatibility Liposomes are biocompatible
Solubility They have the ability to entrap water-soluble
(hydrophilic) and insoluble (hydrophobic) genes
into their internal water compartment and
the membrane, respectively.
Protection Those included into genes are protected from the
inactivating effect of external conditions.
Delivery They give a unique opportunity for the delivery
of genes into target cells.
Size, charge and surface These can be easily changed by adding new
ingredients to the lipid mixture before the
liposome is prepared or through the variation of
methods used to prepare the liposome.
Table 1.3: Applications of liposomes in science.
DISCIPLINE APPLICATION
Biochemistry Reconstitution of membrane proteins into artificial membranes
Biology Model biological membranes, cell function, fusion, recognition
Biophysics Permeability, phase transitions in two-dimensions, photophysics
Chemistry Photochemistry, artificial photosynthesis, catalysis,
microcompartmentalization
Mathematics Topology of two-dimensional surfaces in three-dimensional space
governed only by bilayer elasticity
Medicine Drug-delivery and medical diagnostics, gene therapy
Pharmaceutics Studies of drug action
Physical Chemistry Colloid behaviour in a system of well-defined physical characteristics,
inter- and intra-aggregate forces.
Physics Aggregation behaviour, fractals, soft and high-strength materials
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1.2.2.1.1 LIPOSOMES IN DRUG DELIVERY
The use of liposomes in drug delivery (Table 1.4) is a promising technique but it also presents
certain problems, such as fast removal from the blood and uptake of liposomal samples by
cells of the reticulo-endothelial system, mostly in the liver. Therefore, studies have been
undertaken to develop methods to minimise this problem. One of the developments include
using liposomes with immunoglobulin ligands attached to their surface, which are referred to
as immunoliposomes. The surface ligands are generally able to recognize and transport the
cargo to the target cells (Torchilin, 2005). The commonly used ligands to target liposomes are
immunoglobulins (Ig) of the IgG class together with their fragments. These do not affect the
integrity of the liposome, as it does not bind covalently or via hydrophobic insertion into the
liposome. There are various techniques which have been used to increase circulation half-lives.
These include coating the liposome with polyethylene glycol (PEG) (Figure 1.3) which protect
the liposomes by interfering with their recognition by opsonins in vivo. The use of long-
circulating liposomes has been studied over many years and have been applied in both in vitro
and in vivo biomedical studies. Protective polymers such as PEG are flexible thereby allowing
a small number of surface –grafted polymer molecules to form an impermeable layer over the
surface of the liposome. They are dose dependent, have increased bioavailability and are non-
saturable (Torchilin, 2005).




Table 1.4 Liposomes as drug carriers in the pharmaceutical industry: Adapted from
http://www.remedicajournals.com/liposomes/drug delivery [Accessed 09 November 2013]
Liposome utility Current applications Disease states treated
Accumulation Prostaglandins Cardiovascular diseases
Drug Depot Lungs, sub-cutaneous, intra-
muscular, ocular
Wide therapeutic applicability
Drug protection Cytosine arabinoside, interleukins Cancer
Enhanced Penetration Topical vehicles Dermatology
Extravasation Leaky vasculature of tumours,
inflammations, infections
Cancer, bacterial infections




Solubilization Amphotericin B, minoxidil Fungal infections
Specific Targeting Cells bearing specific antigens Wide therapeutic applicabilit
Sustained-Release Systemic antineoplastic drugs,
hormones, corticosteroids, drug
depot in the lungs
Cancer, biotherapeutics
RES Targeting Immunomodulators, vaccines,
antimalarials, macophage-located
diseases
Cancer, MAI, tropical parasites
Recent studies have focused on the attachment of PEG in a detachable fashion so that the
liposome can be selectively taken up by target cells (Torchilin, 2005). When these PEGylated
liposomes accumulate at the site of interest, PEG is removed under conditions of decreased pH
in tumours. Detachment of PEG is through mild thiolysis of the dithiobenzylurethane linkage
found between PEG and the amino-containing substrate. There have also been studies which
have focused on other polymers that could be used to prepare long circulating liposomes, e.g.
poly[N-(2-hydroxypropyl) methacrylamide)], poly-N-vinylpyrrolidones, L-amino-acid-based
biodegradable polymer–lipid conjugates and polyvinyl alcohol (Torchilin, 2005).
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1.2.2.1.2 LIPOSOMES IN GENE DELIVERY
Liposomes are one of most common non-viral systems for delivering genes into target cells or
organs. Preparing cationic lipid based liposomes is easy, cost effective and they are relatively
non-immunogenic to cells. Liposomes are however still not thoroughly understood and there
are several studies underway which are focused on their function and structure in gene delivery
and the level of transfection efficiency they promote. DNA can be encapsulated in anionic or
neutral liposomes or electrostatically bound to cationic liposomes bringing about condensation
of DNA. Recent studies reported the use of polycationic liposomes for gene delivery.
Polycationic liposomes are liposomes with cetylated polyethelene imine groups (Torchilin,
2005). The polycation anchor into the membrane using the cetyl residues and thereby bind to
DNA using their positive charges. These liposomes have a high transfection efficiency.
Reports on delivery of small interfering RNA using cationic liposomes have also been recently
published (Hattori et al., 2013).
1.2.2.1.3 ADVANTAGES AND DISADVANTAGES OF LIPOSOMES
1.2.2.1.3.1 ADVANTAGES
Liposomes have the ability to increase the therapeutic index of delivered drugs such as
actinomycin-D thereby increasing the efficiency of the drugs. Since anionic /neutral liposomes
encapsulate genes or drugs to be delivered, they tend to increase the stability of the genes (Dua
et al., 2012). Liposomes are biocompatible and relatively non-immunogenic to the target
organ. The non-toxicity and the ability of them to be completely biodegradable is an advantage
of using them for both in vitro and in vivo purposes. Reports show that using liposomes reduces
the toxicity of the drug or gene which is encapsulated within it. Liposomes are also known to
play a role in the reduction of exposure of sensitive tissues to the toxic agent. These liposomes
have the flexibility to bind to site-specific ligands (Akbarzadeh et al., 2013).
1.2.2.1.3.2 DISADVANTAGES
Generally, unmodified liposomes have a short half-life. It was also reported that using
liposomes can be a disadvantage because the phospholipids can sometimes undergo hydrolysis
and oxidation-like reactions (Dua et al., 2012).
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1.2.2.2 DELIVERY PATHWAYS AND CELLULAR BARRIERS
When designing a non-viral system for gene delivery, it is necessary to identify all the cellular
barriers which has to be overcome by the vector during the gene delivery process.  Firstly, the
DNA must be able to interact with this vector since the half-life of naked DNA is increased by
the vector which protects DNA from degradation by proteases (Pathak et al., 2009). DNA
condensation can be achieved by using cationic compounds that form electrostatic interactions
with the DNA phosphate group, and can interact with the lipids using hydrophobic interactions.
DNA collapses when neutral lipids such as PEG are highly concentrated, resulting in the DNA
molecules forming compacted particles via non-specific interactions with an exclusion of
solvent volume. When complexes are formed, they then have to cross the plasma membrane
of the target cells (Katragadda et al., 2010). Therefore, a ligand-containing vector should be
able to undergo internalisation by processes such as receptor-mediated endocytosis. If there is
no ligand then the complex can be degraded by serum nucleases, or as in many cases the
complexes are taken up by an adsorption process. There are different ligands which maybe be
employed e.g. folic acid, transferrin and epidermal growth factor (EGF), for cancer cells. After
binding and entry into the target cell /tissue, the complex should be able to escape from the
endosome into the cytosol. PEI, a common polymer in gene delivery, can be used to achieve
this, as it destabilizes the endosomal membrane and allows the complex to escape through a
process known as the proton sponge effect (Katragadda et al., 2010).
1.3 RECEPTOR MEDIATED ENDOCYTOSIS
Receptor mediated endocytosis involves the internalization of molecules including viruses.
This process is highly dependent on the molecules interaction with a specific binding protein
(receptor) on the cell membrane (Gaidarov et al., 1999). There are different major types of
events which occur during the internalization of molecules. The ways in which cells internalize
molecules can be seen in Figure 1.4.
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Figure 1.4: Events which occur during internalization of molecules in cells: Adapted from
http://www.cytochemistry.net/cell-biology/recend.htm#internalization
[Accessed 14 July2014].
During phagocytosis, bacteria or other cells are internalised without the need of a receptor. In
the case of pinocytosis, soluble material is generally internalised by the cells, also without the
need for receptors. In these processes, the complexes or molecules are captured into the
vacuole (phagosomes or macropinosomes). However, during receptor-mediated endocytosis,
endosomes are formed into which the complexes or molecules are enclosed (Gaidarov et al.,
1999). Specific binding to the receptor is important for this receptor-mediated endocytosis to
occur. This process is shown as the coated pit endocytosis in Figure 1.4. The coated pit is a
specific region found on the cell membrane and is coated with clathrin which ensures stability
and assists during transportation. During endocytosis, this coated pit region forms a vesicle
which loses its clathrin coat and joins with other coated pits to form a receptosome (Figure
1.4) (Gaidarov et al., 1999).
1.3.1 PATCHING AND CAPPING
During receptor-mediated endocytosis, the ligand binds to its specific receptor on the surface
of the cells. The complex formed between receptor and ligand (ligand-receptor complex) is
stored in the clathrin coated pits. Different things occur in different cells, however, in most
cells the coated pits with complexes concentrate in a certain cell area and these appear as
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patches of label on the surface of the cell, thus the process is termed patching (Gaidarov et al.,
1999). These then merge and form a cap at one pole inside the cell, the process is called
capping.  This process of pre-concentrating enables the cell to control the amount of fluid that
is taken up by the vesicle.
1.3.2 FORMATION AND FUNCTION OF CLATHRIN-COATED PITS
During receptor-mediated endocytosis, the clathrin coats mount the pit and form clathrin
coated pits (Figure 1.5). Formation of these molecules causes the pit to invaginate, and help
stabilise the vesicles that bud from the cell membrane. The clathrin-coated pits are known to
move in the membrane plane.
Figure 1.5: Formation of clathrin-coated pits during receptor- mediated
endocytosis: Adapted from Adapted from http://www.cytochemistry.net/cell-
biology/recend.htm#internalization [Accessed 14 July2014].
.
Studies have shown that there is an organised movement of the clathrin coated pits.  One of
the studies involved transfecting cells with a green fluorescent protein carrying plasmid DNA
which was attached to the clathrin light chain (Gaidarov et al., 1999). This study showed the
disappearance and appearance of clathrin coated pits at different intervals. The clathrin coat is
lost from the pits which then form vesicles in an energy dependent process resulting in the
formation of the endosomes or receptosomes.
16
In the cytoplasm, the vesicles lose their coat and fuses with other similar vesicles in a process
known as the hymotypic fusion. During early endosome formation, most of the incoming
components from the membrane are recycled back from the early endosome to the membrane
of the cell while a large fraction of the molecules are taken to the late endosome (Figure 1.6).
The late endosome is formed by the continual drop in pH to about 5-6. The late endosomes are
important because they contains digestive enzymes which degrade most lipids and proteins
and also recycle some receptors. Finally, the endosome fuses with the lysosomes which are the
highly acidic vacuoles containing hydrolases, forming endolysosomes where molecules are
digested (Gaidarov et al., 1999).
Figure 1.6: Formation of early, late endosome and lysosome during receptor mediated
endocytosis: Adapted from http://www.cytochemistry.net/cell-biology/recend2.htm
[Accessed 14 July 2014].
One example where receptor mediated endocytosis is used by the cells to take up molecules
involves the uptake of the low density lipoprotein (LDL) which was first published in 1994
(Alberts et al., 1994). This model shows the uptake of cholesterol bound to LDL by the cell.
In this study the receptors were recycled and the LDL-cholesterol ligand was taken up with
cholesterol being released into the cell where it was metabolised. One of the most commonly
studied receptors in receptor mediated endocytosis is the asialoglycoprotein receptor which is
found almost exclusively on the surface the liver cells (Gaidarov et al., 1999).
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1.4 ASIALOGLYCOPROTEIN RECEPTOR (ASGP-R)
The asialoglycoprotein receptor (also known as the hepatic lectin) is a C-type, calcium ion-
dependent lectin which is expressed only on the surface of the parenchymal hepatocytes
(Rensen et al., 2001). These ASGP-R receptors are distributed randomly over the sinusoidal
plasma membrane which faces the capillaries. ASGP-R was discovered by Ashwell and Morell
in 1974. The fact that the ASGP-R is highly expressed in the hepatocytes and is an efficient
ligand for endocytosis makes it an important target for liver gene delivery (Wu et al., 2002).
The ASGP-R specifically binds to glycoproteins which have terminal galactose or the N-
acetyl-galactosamine residues, and to desialylated tri or tetra-antennary N-linked glycans (Wu
et al., 2002).
1.4.1 ASGP-R STRUCTURE
Hepatocytes contain approximately 100 000 – 500 000 ASGP-R binding sites per cell. The
ASGP-R found in humans has two homologous subunits, which are H1 and H2 (46 kDa and
50 kDa, respectively) (Wu et al., 2002). These subunits are type II membrane proteins,
comprising of a cytoplasmic N terminus made up of 40 amino acid residues, an exoplasmic C
terminus made up of approximately 230 amino acid residues and a transmembrane domain.
Found in these domains is a stalk segment made up of about 80 amino acid residues and also
a carbohydrate recognition domain. It is due to the multiple interactions of this recognition
domain that the receptor has the high ligand binding specificity and affinity (Meier et al.,
2000). These subunits form a non-covalent hetero-oligomeric complex by the alpha-helical
coiled coil domains with an estimated ratio of 2.5:1. The subunits are single spanning
membrane proteins with a calcium-dependent D-galactose/ D-N-acetylgalactosamine
recognition domain (Rensen et al., 2001). The recognition of the carbohydrate moiety is
mediated through the H1- subunit, while the H2- subunit accounts for the functional
configuration of the native receptor.
1.4.2 STRUCTURE OF THE CARBOHYDRATE RECOGNITION DOMAIN
(CRD) OF H1 SUBUNITS
Beta-strands of the CRD form a protein core as they are arranged in a bent plane form with the
alpha-helices located on either side of the plane. There are three sheets which extend in
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different directions from the protein core (Meier et al., 2000). The protein core is formed by
the beta 3 strand which is at the middle of the glycine residue 212 and is bent at an angle of
about 90 degrees.  The glycine loop protrudes from the surface of the protein, and thus forms
the sugar-binding site. The CRD has an N-terminus which has a disulphide bridge connection.
Also present on this structure are three calcium ion binding sites. This CRD region is
responsible for the high binding affinity and specificity for carbohydrates as is shown in Figure
1.7. Here the blue strips represent the beta-strands while the green balls represent the calcium
ions and the yellow lines showing the disulphide bridges (Meier et al., 2000).
Figure 1.7: Stereoscopic ribbon diagram of the H1-CRD of ASGP-R: Adapted from Meier
et al., (2000).
1.4.3 THE GALACTOSE-BINDING SITE
This is the region that defines the sugar-binding site and has a polpeptide chain which stretches
continuously from Arg236 to Cys268. There is also a glycine-rich loop and has a beta-turn
between Thr258 and Arg262. This region therefore has three segments which are in contact
with the calcium ions. In this site, there are two metal ions separated by 8.5 Å. The three
segments are located within metals and the glycine-rich loop extends and attaches to the
Asp215-Trp220 loop. Two of the three segments have a beta-strand conformation. These
characteristics of the galactose-binding site of the asialoglycoprotein receptor are shown
clearly in Figure 1.8 (Meier et al., 2000).
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Figure 1.8: Overlay of the sugar-binding site of the H1-CRD of the ASGPR (grey)
containing an N-acetyl galactosamine molecule as ligand (green): Adapted from Meier et al.,
(2000).
1.4.4 PHYSIOLOGICAL ROLE OF ASGP-R
The function of the ASGP-R is to maintain serum glycoprotein homeostasis by recognition,
binding, and the entry of asialoglycoproteins by endocytosis. Studies have revealed that
patients with liver cancer have high levels of asialoglycoproteins, arising from impaired
function of ASGP-R (Geffen and Spiess, 1992). Furthermore, the ASGP-R is responsible for
the uptake of glycoproteins which is essential for the liver. An example of such a glycoprotein
is immunoglobulin A (IgA) that contains terminal Gal and GalNAc residues on its
oligosaccharide chains (Brown and Koppel, 1986).  During endocytosis the receptor clears the
ligand proteins from the circulation, and these ligand proteins are eventually degraded, and
the receptor is recycled back to the cell surface. In this case, the ASGP-R provides a
degradative pathway for serum glycoproteins. According to a report by Treichel et al. (1997),
certain viruses such as the hepatitis B virus and the Marburg virus may cause infection using
these receptors. However, these receptors play a major role in the delivery of genes and drugs.
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1.5 THE LIVER AS A TARGET FOR GENE DELIVERY
The liver (Figure 1.9) is an essential target organ for gene delivery as it plays a central role in
metabolism and is also important in serum protein production. Many debilitating metabolic
diseases associated with deficiency of hepatocyte derived gene products have been reported.
These disease can be targeted through delivery of therapeutic genes to the liver (Hara et al.,
1997). Furthermore, diseases such as hepatoma and viral hepatitis can be targeted using hepatic
gene therapy. There are important factors which contribute to the improvement of hepatic gene
therapy, one of them being the degree of development of an ideal delivery system which can
efficiently introduce the therapeutic genes into the hepatocytes. Various methods have been
used to deliver genes into the liver, albeit with some disadvantages.
Figure 1.9: Image of the liver: Adapted from
http://lookfordiagnosis.com/mesh_info.php?term=liver+diseases&lang=1
[Accessed 10 October 2013].
Viral vectors such as the retroviral vectors have been used to introduce genetic material into
the liver. Retroviral vectors however do not infect quiescent cells, and for this reason they have
been used mostly for ex vivo delivery of genes, e.g. they have been used in transduction of
hepatocytes which have been cultured and subsequently re-implanted into the host liver (Hara
et al., 1997).
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On the other hand, direct introduction of genetic material into the liver requires improved
propagation activity of the hepatocytes. Propagation can be achieved through partial
hepatectomy. In some cases, adenoviral vectors have been used to deliver genes into the liver.
The introduction of these vectors by injection into the portal vein leads to increased levels of
foreign gene expression. However, transient expression is usually observed and repetitive
injection is not conducive because of the high immunogenicity of the adenoviral vector. The
non-viral gene transfer methods which have been described earlier (section 1.2.2) include
injection of plasmid DNA alone, but in most cases plasmid DNA is complexed with polymers
such as polylysine or with liposomes (Hara et al., 1997). These are still being studied, although
they have the disadvantage of producing low levels of gene expression which is insufficient
for therapeutic use. In the systemic circulation, there are lipoproteins which carry cholesterol
and other lipids.
Studies have recently shown that reconstituted chylomicron remnants which have been
produced from commercially-available lipids are taken up by hepatocytes following
intravenous injection. These remnants are produced during the circulation of blood where the
triglycerides-rich lipoproteins are remodelled to chylomicron remnants through the hydrolysis
of core triglycerides by lipoprotein lipases and by binding apolipoproteins (Hara et al., 1997).
The liver parenchymal cells then take up the remnants through the apolipoprotein-specific
receptors. Non-viral particles resulting from inclusion of beneficial DNA into reconstituted
chylomicron remnants could be a competent vector for gene delivery to the liver (Hara et al.,
1997). There have been studies conducted on the inclusion of DNA into reconstituted remnants
through hydrophobic DNA complex formation with quaternary ammonium derivatives of
cholesterol. Studies showed that when these were introduced into the liver, there was high
expression of foreign genes. The therapeutic potential of the novel vector has then been shown
in humans, with the expression of the 1-antitrypsin (hAAT) gene in the liver (Hara et al., 1997).
1.6 CHOLESTEROL
Cholesterol is a naturally occurring lipid which is metabolized in the body. The development
of novel cholesterol based cationic lipids gained momentum after the gene delivery using DC-
Chol lipid was successful demonstrated in 1991 by Gao and Huang. The T-shaped headgroups
of cationic lipids are more effective in delivering genes compared to the linear type. Reports
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have shown that the T-shape spermine and spermidine cholesteryl carbamate have a 50-100
fold higher efficiency both in vitro and in vivo when compared to the level of gene expression
achieved by DC-Chol (Wang et al., 2002). The advantages of lipids and polycations were
combined by synthesizing lipopolylysine. Poly (L-lysine) with molecular weight 3300 Da was
mixed with the N-hydroxysuccinimide ester of dipalmitoylsuccinylglycerol in dimethyl
sulfoxide. These were synthesized using the solid phase synthesis method. Reports have also
shown that preparing liposomal formulations with cationic amphiphiles and using DOPE
enhances gene delivery. Cetyl groups were also used as hydrophobic lipid anchors onto PEI
and later used to prepare polycation liposomes for gene delivery (Mahato, 2005).
Figure 1.10: Structure of cholesterol: Adapted from
http://www.diagnosisdiet.com/food/cholesterol/ [Accessed 10 October 2013].
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1.7 OUTLINE OF THESIS
1.7.1 AIMS AND OBJECTIVES:
The aim of this project was to formulate and utilize non-viral hepatocyte targeted cationic
liposomes. The galactose ligand incorporated into the liposomal formulation was used for the
ligand-receptor recognition. The human hepatocellular carcinoma cells (HepG2) which has the
asialoglycoprotein receptor which recognises and binds to the galactose moiety was used as
the target cell line while a ASGP-R negative (HEK293) cell line was used as a control. The
objectives were:
 to prepare cationic liposomes (PEGylated/targeted/acetylated) using novel cholesterol
derivatives according to the lipid film hydration method.
 to characterize the liposomes and liposome-DNA complexes (lipoplexes) using
transmission electron microscope (TEM) and Zeta sizing.
 to perform DNA binding studies using gel retardation, nuclease digestion and ethidium
bromide intercalation assays.
 to assess cytotoxicity to cell lines in vitro using the MTT assay.
 to evaluate luciferase activity using the luciferase reporter gene assay.
 to perform competition assays to confirm lipoplex entry is by receptor mediated
endocytosis.
Chapter one includes the introduction and literature survey on gene therapy concentrating on
non-viral gene delivery vehicles viz. liposomes. Chapter two provides a brief introduction and
detailed account of the synthesis and preparation of the different cationic liposome
formulations and their characterisation using electron microscopy and zeta sizing. Chapter
three includes a short introduction, description and discussion of the different assays performed
to determine liposome: DNA binding viz. gel retardation, nuclease protection, and ethidium
bromide intercalation studies. Chapter four outlines the cell culture assays undertaken in vitro.
This includes an introduction to cell culture, including results and discussions of the MTT cell
viability assays and the luciferase transgene activity. Lastly a brief conclusion is provided
taking into account the results obtained and future work that needs to be done.
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CHAPTER TWO
2. LIPOSOME PREPARATION AND CHARACTERISATION
2.1 INTRODUCTION
Liposomes can be defined as hollow spheres of lipids or vesicles which have a similar lipidic
composition to the cell membrane. The term liposome is taken from the Greek words, ‘lipos’,
which means fat and ‘soma’, which means body.  Dr Alec D Bangham was the first scientist
to describe liposomes in 1961, and published this data in 1964 (Bangham and Horne, 1964).
This discovery of the liposome was done at the Babraham Institute (Cambridge), where Dr
Bangham and R.W. Horne were simply testing the new electron microscope at the institution.
These two scientists added negative stain to the dry phospholipid and hence discovered
liposomes. The liposome resembled the plasmalemma, and pictures taken using that
microscope were the first real images of a liposome.
The structure of the membrane involves a lipid bilayer which encloses an aqueous
compartment. The bilayer is made up of phospholipids with the hydrophobic tails on the inside
and the hydrophilic head groups on the outside (Figure 2.1). The hydrophilic head groups, are
attracted to water and hydrophobic tails commonly made up of long hydrocarbon chains are
repelled by water. Generally, the two head groups in the bilayer face opposite directions while
the tails face each other. This structural form makes it a bilayer while the formation of a
monolayer structure is termed a micelle. Phospholipids found in the plasma membrane are
usually phosphatidylethanolamine and phosphatidylcholine. However, liposomes can have
naturally- derived phospholipids which have mixed lipid chains i.e. phosphatidylethanolamine
or they can be made of pure surfactant components such as DOPE
(dioleoylphosphatidylethanolamine).
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Figure 2.1: Diagram showing the different modifications of a liposome: Adapted from
http://www.nature.com/nature/journal/v489/n7416/fig_tab/489372b_F1.html [Accessed 12
October 2013].
There are different types of liposomes which can be classified according to their structural
parameters, preparation method and their composition and applications as seen in Table 2.1
and Figure 2.2 respectively.
Table 2.1 Classification of liposomes based on their structural parameters.
Vesicle Types Diameter Size Number of lipid bilayers
Small unilamellar vesicles
(SUV)
20-100nm. One lipid bilayer
Large unilamellar vesicles
(LUV)
100nm. One lipid bilayer
Multilamellar vesicles
(MLV)











2.1.1 HANDLING OF LIPOSOMES
There are a few important things to take note of when handling or using liposomes in the
laboratory. Since liposomes are prepared using lipids, this makes them susceptible to oxidation
because the lipids which are used during preparation are unsaturated. Also chloroform which
is commonly used when preparing liposomes, is a volatile solvent which tends to evaporate
when exposed to the atmosphere. Hence, it is important to store liposome preparations in an




















Conventional Liposomes Neutral / -vely chargedphospholipids and cholesterol
Fusogenic Liposomes Reconstituted Sendai virus
pH sensitive Liposomes Using phospholipids such asPE or DOPE
Cationic Liposomes Cationic lipids containingDOPE
Long circulatory or stealth
Liposomes
High Tc made using
cholesterol
Immuno-liposomes With attached monoclonalantibody
Figure 2.2: Classification of liposomes based on composition and application: Adapted from Dua
et al., (2012).
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2.1.2 LIPOSOMES AND CELLULAR ENTRY
There are four ways with which liposomes interact with cells in order to gain entry.
 Endocytosis: this is a process where liposomes enter cells through phagocytosis and
occurs commonly with cells of  the reticulo endothelial system e.g. neutrophils and
macrophages
 Adsorption: liposomes are taken up by the cell through electrostatic or nonspecific
weak hydrophobic forces or through specific interactions with the cell-surface
components.
 Cell fusion: liposome fuses with the plasma membrane of the cell by inserting its lipid
bilayer into the plasma membrane, and the liposome contents is released into the
cytoplasm at the same time.
 Lipid transfer into cell membranes: lipids are transferred into the cellular or subcellular
membranes and vice versa (Gaurav and Tejal, 2011)
2.1.3 METHODS OF PREPARATION OF LIPOSOMES
There are different methods which can be used to prepare liposomes. These includes lipid
hydration or thin-film hydration method, solvent spherule method, sanitation method
(sonication), French pressure cell method, solvent injection methods, and detergent removal
methods amongst others (Gaurav and Tejal, 2011). Thin-film hydration provides a quick and
easy protocol to prepare concentrated and homogeneous suspensions of small unilamellar
liposomes. The liposomes prepared by thin-film hydration are suitable for laboratory-scale
animal experiments. It involves the formation of a thin film of dried lipids on the walls of a
round bottom glass flask. This is followed by the hydration of these lipids in aqueous solutions
such as phosphate buffered saline (PBS) to form a suspension of lipids that could be either
unilamellar or multilamellar. In many cases, this is followed by the passage of the lipid
suspension through polycarbonate filters of specific pore sizes. The shear force due to the lipid
passage through the membrane produces unilamellar liposomes. Liposome sizes are based on
the pore size of the filters through which the lipids are filtered. If one needs to prepare
liposomes for large scale purposes, microfluidization should be employed (Sorgi and Huang,
1996).
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This chapter reports on the preparation of six novel cationic liposomes. All these liposomes
contain the cholesterol derivative, 3 β [N-(N’, N’-dimethylaminopropane)-carbamoyl]
cholesterol (Chol-T) and the neutral lipid dioleoylphosphatidylethanolamine (DOPE). Three
of which are PEGylated and acetylated and the other three are non-acetylated and not
PEGylated. Characterization of all liposome preparations was performed by transmission
electron microscopy.
2.2. MATERIALS AND METHODS
2.2.1. MATERIALS
Chol-T cationic lipid 3β[N-(N’,N’-dimethylaminopropane)-carbamoyl] cholesterol was
synthesized following a previously published procedure (Singh et al., 2001).
Dioleoylphosphatidylethanolamine (DOPE) was purchased from the Sigma Chemical
Company, St Louis, USA. The acetylated and non-acetylated galacto compounds were
synthesized in the Department of Chemistry, University of the Witwatersrand, South Africa.
HEPES buffered saline (HBS) was purchased from Merck, Darmstadt, Germany. 1,2-
Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene-glycol)-2000]
ammonium salt (PEG2000) was purchased from Avanti Polar Lipids, Alabaster, USA.
2.2.2 METHODS
2.2.2.1 LIPOSOME PREPARATION
The six cationic liposomes were prepared using the thin film hydration method. The
components and quantities used are presented in Table 2.2. The liposome preparations were
made up to contain a total of 4 μmoles of lipid in 1 ml of HBS. All six liposomes contained
DOPE and the cytofectin 3 β [N-(N’, N’- dimethylaminopropane)-carbamoyl] cholesterol
(Chol-T) (Figure 2.3 A). The structures of the acetylated and deacetylated compounds used are
shown in Figure 2.3.B Chloroform was employed during the preparation of liposomes to
solubilise the liposome lipidic components. This was then mixed and deposited as thin films
on the walls of the quick fit tubes by rotary evaporation of the suspension in vacuo (Büchi
Rotavapor-R). Samples were dried under high vacuum in a drying pistol for 24 hours. The thin
film was then rehydrated in a total volume of 1 ml containing sterile HBS (20 mM HEPES and
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150 mM NaCl, pH 7.5). All preparations were vortexed and hydrated overnight. Following
this, preparations were sonicated for 5 minutes in a sonicator (Labotech Transsonic 460/H, 220
– 240 V/AC) at a frequency of 35 kHz to produce unilamellar liposomes.
Figure 2.3:  A: Structure of cationic cytofectin Chol-T. B: The structures of the acetylated
Sc-2 (Cholest-5-en-3-yl 2-[2-(2-{2-[4-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-1-






















1 2 1.49 2 1.03 - - - - - -
2 1.8 1.34 2 1.03 - - - - 0.2 0.56
3 1.6 1.19 2 1.03 - - 0.4 0.34 - -
4 1.4 1.04 2 1.03 - - 0.4 0.34 0.2 0.56
5 1.6 1.19 2 1.03 0.4 0.41 - - - -
6 1.4 1.04 2 1.03 0.4 0.41 - - 0.2 0.56
2.2.3     LIPOSOME CHARACTERIZATION BY TRANSMISSION ELECTRON
MICROSCOPY (TEM).
Cationic liposomes in HBS were diluted 1:5 to promote fluidity of the samples. Aliquots      (1
μl) of each diluted sample were placed on a Formvar coated grid. Uranyl acetate (0.5%)
negative stain was mixed into the sample. Grids were allowed to stand for 3 – 5 minutes. A
spring-loaded Leica CPC system was used to plunge samples into liquid nitrogen cooled
propane gas. Grids were then viewed under the JEOL 1010 TEM without warming above -
150ºC. The electron micrographs were examined to observe the size and dimensions of the
liposome formulations.
2.2.4 ZETA SIZING
A Malvern Zetasizer Nanoseries (Malvern Instruments, Worcestershire, UK) was used to
measure the hydrodynamic diameters of all six cationic liposomes. All cationic liposomes were
diluted 1:20 with HBS before measurements were taken. These diluted samples were then
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vortexed to completely suspend and ensure even distribution of the liposomes in the HBS. The
sizes of the cationic liposomes were measured using the zetasizer at a refractive index of 1.450.
2.3 RESULTS AND DISCUSSION
2.3.1 CATIONIC LIPOSOMES PREPARATION
Cationic liposomes were prepared using the thin film rehydration method as described in
section 2.2.2.1. A total of six cationic liposomes were prepared, each containing the cytofectin
Chol-T and the neutral co-lipid dioleoylphosphatidylethanolamine (DOPE). DOPE functions
as the helper lipids in these cationic liposome preparations to enhance transfection efficiency.
Chol-T has a dimethylamino head group which is protonated at physiological pH (pH 6-8).
Chol-T therefore shows a positive charge and tends to form stable liposomes when mixed with
equal number of moles of DOPE (Singh et al., 2011). DOPE exhibits transitions in structure
with changes in pH. Above pH 9, DOPE forms a spherical micelle-like structure, which then
transforms to an inverted hexagonal form at an acidic pH. This structural change plays an
important role in the fusion and the destabilization of the endosomal membrane. It has been
reported that DOPE destabilizes the binding that occurs between the cationic lipids and DNA,
thus allowing the DNA to be released from lipoplexes (Mochizuki et al., 2012).  There have
been several reports that investigate the responsiveness of micelles made from DOPE in order
to understand the molecular origin of pH dependence of DOPE (Mochizuki et al., 2012).
The structure of the cationic cytofectins consist of a cholesterol ring anchor, a carbamoyl linker
bond and a monovalent dimethylamino head group. Some of these liposomes have hydrophilic
polymers such as poly(ethylene glycol (PEG) and targeting ligands such as galactose moiety
which have an affinity for the  asialoglycoprotein receptor (ASGP-R), predominantly found in
hepatocytes and hepatocyte -derived cells. The hydrophilic nature of PEG helps inhibit plasma
proteins from adsorbing onto the carrier’s surface, resulting in an increase in the carrier’s
systemic circulation time and enhancing the possibility of transfection.  In the case of the
acetylated liposomes, the effect of O-acetylation on the hydroxyl groups of the liposome-
bound galactose has yet to be fully explored. The incorporation of cholesterol is important as
it plays a vital role in controlling fluidity and permeability of the membrane and hence ensuring
stability of the formulation (Obata et al., 2009).
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2.3.2 TRANSMISSION ELECTRON MICROSCOPY (TEM) OF LIPOSOMES
TEM uses a high energy beam of electrons to provide specific images of the sample. These
electrons interact with the atoms and one can observe features such as the structure, shape and
size of the samples. The six cationic liposome formulations used in this study displayed
unilamellar, spherical-like morphologies but varied in their sizes from 50 to 200 nm in
diameter (Figure 2.4). Studies have revealed that cationic liposomes can be classified
according to their structure and size.  According to Immordino et al., (2006), unilamellar
liposomes have a large aqueous core and such liposomes are preferred when encapsulating
water-soluble drugs. The differences in sizes of these six cationic liposomes could be due to
their varied lipid, polymer and carbohydrate compositions.
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Figure 2.4: Transmission electron micrographs of the six cationic liposomes. The average
diameter of each of the liposomes were: A: DOPE + Chol-T (Bar = 100 nm); B: DOPE + Chol-
T + PEG (Bar = 100 nm); C: DOPE + Chol-t + Sc-5 (Bar = 100 nm); D: DOPE + Chol-T +
Sc-5 + PEG (Bar = 200 nm); E: DOPE + Chol-T + Sc-2 (Bar = 50 nm); F: DOPE + Chol-T +





Overall from the TEM images, it was observed that the PEGylated liposomes in all cases
appeared smaller in size (70 – 105 nm) than that of the non-PEGlated liposomes (150- 200
nm). This could be due to the PEG chains on the liposome surface which are thought to prevent
vesicle aggregation (Immordino et al., 2006).
2.3.3 ZETA-SIZING
Table 2.3 shows the hydrodynamic diameters of the cationic liposomes as determined from
zeta-sizing. From these results, it was noted that the sizes of the liposomes were varied which
is similar to what was seen under TEM. The size of the liposomes overall ranged from 79.99
nm for the targeted PEGylated liposome to 198.9 nm for the targeted acetylated liposome. Here
again the results show that the PEGylated liposomes are much smaller than their non-
PEGylated counterparts. The polydispersity index (PDI) for all liposomes were around 0.2. A
PDI around 0.1 generally signifies a monodisperse system (Cabral et al., 2004). The PDI
obtained for these liposome are still low, indicating that much of the liposome populations may
be monodisperse and only slightly heterogeneous.
Table 2.3: Sizes and Polydispersity of the different cationic liposomes.









3. PREPARATION AND CHARACTERISATION OF LIPOPLEXES
3.1 INTRODUCTION
Cationic liposomes have been widely used in vitro to condense DNA, thus forming lipoplexes
(Figure 3.1). Lipoplexes may be defined as self-assembling nanosystems. There have been two
different models which have been proposed to understand the structures of lipoplexes formed
between plasmid DNA and cationic lipids. The first model is known as the external model,
where the plasmid DNA is adsorbed onto the cationic liposome surface. The second model; is
known as the internal model, where the plasmid DNA is coated by the lipid envelope (Ma et
al., 2007).
Figure 3.1: Formation of the lipoplex by binding of cationic liposome and plasmid DNA:
Adapted from http://www.uweb.engr.washington.edu/research/tutorials/drugdelivery.html
[Accessed 09 September 2014].
The second model however involves various steps during the mechanism of the lipoplex
formation.  These steps have been studied using lipid monolayers, cryo-electron microscopy
and atomic force microscopy, and has shown that the first step in the formation of lipoplexes
occurs within a millisecond, where the DNA interacts with the amine head groups (positively
charged) of the cationic lipids through electrostatic interactions. This interaction on one side
or surface of the DNA and the liposome causes packing constraints within the bilayer, resulting
in widespread interactions between adjacent bilayers as well. This is followed by the release
of the contents of the vesicle which shows that the membrane structure has been broken,
causing the hydrophobic edges to be exposed.  These edges may serve as the nucleation sites
where adjacent structures interact with each other, thus causing more merging of membranes
and mixing of lipids. As time goes by, the cationic liposome becomes completely bound around
the plasmid DNA. The complex formed has a smooth surface which shows that the DNA has
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been properly packaged within the cationic liposome. At this point, lipid mixing stops because
sites where there can be potential interaction are blocked. It is important for the cationic lipid
to compact the DNA effectively, and to maintain its elasticity. Easily hydrated lipids form fluid
aggregates which then undergo a transition to form an inverted hexagonal phase when plasmid
DNA is introduced at physiological ionic strength. These lipids often produce high transfection
efficiencies. Neutral lipids that are usually incorporated in the cationic liposome, play vital
roles in the formation and functioning of the lipoplex.
In this study, the neutral lipid DOPE was used when preparing the cationic liposomes. DOPE
is known to have an effect on the polymorphic features of the lipoplex because it can induce
the lamellar to hexagonal phase transition. Also, the presence of DOPE results in cationic
charges being neutralised by the phosphodiester bond which is negatively charged (Wasungu
and Hoekstra, 2006). The lamellar structure is the most common phase that lipoplexes assume
with plasmid DNA in between the cationic bilayers. Several factors do however affect the
behaviour of the lamellar and hexagonal phase. Figure 3.2 shows different structures which
can be assumed by lipoplexes formed by cationic liposomes and plasmid DNA.  For a lamellar
morphology (Figure 3.2 a), the rods of DNA are located between the lipid bilayers of the
cationic liposome. In the hexagonal lattice (Figure 3.2 b), the rods of DNA are coated with the
cationic liposome monolayer and  lastly, as seen in Figure 3.2 c, the rods of DNA are covered
by three honeycombs of cationic lipid micelles and these micelles are also arranged as a
hexagonal lattice.
Studies have revealed that the structure of the lipoplex and it stability is dependent upon the
molecular characteristics of cationic and helper lipids as well as on the cationic liposome to
plasmid DNA ratio. Ionic strength and temperature also have an effect on the behaviour or
functioning of the lipoplexes. The lamellar phase lipoplexes are known to be stable over a wide
range of temperature and ionic strengths (Ma et al., 2007).
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Figure 3.2: Different phases of lipoplexes with (a) a lamellar structure formed from the
mixture of cationic lipid and plasmid DNA, (b) an inverted hexagonal structure, and
(c) an intercalated hexagonal structure. Adapted from Ma et al., (2007).
Efficient transfection or gene expression is dependent on different factors such as the ability
of DNA to be transported successfully to the target site without leakage or being degraded by
cytoplasmic enzymes or serum nucleases. Other factors may include easy escape of the DNA
from the endosomal compartment. A number of assays have been developed to characterize
the liposome-DNA association and the results obtained have been correlated with transfection
efficiency. These include gel retardation, nuclease protection and ethidium bromide
intercalation assays. These three assays determine whether the cationic liposomes can
efficiently bind the plasmid DNA and protect it from the action of nucleases, and indicate the
degree of cargo DNA condensation respectively.
3.2 MATERIALS AND METHODS
3.2.1 MATERIALS
Ethidium bromide was acquired from Merck, Damstadt, Germany. Plasmid DNA (pCMV-luc)
was obtained from Plasmid Factory, Bielefeld, Germany. Agarose was purchased from Bio-
Rad Laboratories, California, USA.  All other reagents were of analytical grade.
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3.2.2. METHODS
3.2.2.1 GEL RETARDATION ASSAY
Agarose gel electrophoresis was performed using a 1% agarose gel prepared by dissolving 0.2
g of agarose powder in 18 ml of distilled water. The agarose mixture was heated to boiling
point in order to dissolve the entire agarose powder. This was followed by cooling to
approximately 75 oC, followed by the addition of 2 ml of 10x electrophoresis buffer (0.36 M
Tris HCl, 0.3 M NaH2PO4, 0.1 M EDTA, pH 7.5), and 1.5 µl of ethidium bromide solution (1
µg/ml). The agarose solution was allowed to cool further to a temperature of about 60-62 oC
and then poured into a sealed casting tray containing an 8 well comb. Various ratios of cationic
liposome-DNA complexes were prepared as follows: plasmid DNA (0.5 µg) was added to
increasing volumes of cationic liposome dispersions in HBS (Table 3.1). The plasmid DNA–
cationic liposome complexes were subjected to brief vortexing, centrifugation and then
incubated at room temperature for 30 minutes. Thereafter, 3 µl of gel loading buffer (40 %
sucrose, 0.5 % w/v bromophenol blue) was added to all complexes and samples  loaded into
the wells of the agarose gel in a Bio-Rad mini-sub electrophoresis apparatus containing 1x
electrophoresis buffer (36 mM Tris HCl, 30 mM NaH2PO4, 10 mM EDTA pH 7.5).  Gels were
run at 50 volts for 90 minutes and then viewed under UV transillumination at 300 nm and
images were captured using a Vacutec Syngene G: Box gel documentation system (Syngene,
Cambridge,UK).




1:0 1:1 1:2 1:3 1:4 1:5 1:6 1:7
DNA
(0.5 µg/ µl) (µl)
1 1 1 1 1 1 1 1
Diluted
liposome (µl)
- 3.75 - - - - - -
Undiluted
liposome (µl)
- - 1.5 2.25 3 3.5 4.5 5.25
HBS (µl) 9 5.25 7.5 6.75 6 5.8 4.5 3.75
Total volume
(µl)
10 10 10 10 10 10 10 10
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3.2.2.2 NUCLEASE PROTECTION ASSAY
Complexes were prepared as described in section 3.2.2.1 but using the sub-optimal, optimal
and supra-optimal ratios for each complex. The samples were incubated at room temperature
for 30 minutes, followed by the addition of foetal bovine serum (FBS) to the complexes to a
final concentration of 10 % (v/v). Two controls were also prepared, one containing plasmid
DNA only and a second containing plasmid DNA and FBS. The samples containing FBS were
further incubated at 37°C for 4 hours. Following the incubation period,
ethylenediaminetetraacetic acid (EDTA) was added to all samples to a final concentration of
10 mM. EDTA acts as the chelating agent for divalent cations thus stopping the nuclease
reaction. Sodium dodecyl sulphate (SDS) was then added to a final concentration of 0.5%
(w/v) to break the interactive forces between the liposomes and the DNA and to allow the
DNA to be released from the lipoplexes. Thereafter, the samples were incubated at 55°C for
20 minutes. Samples were then subjected to agarose gel electrophoresis at 50 volts for 120
minutes. Gels were then viewed and images captured as in section 3.2.2.1.
Table 3.2: Ratios of liposome: DNA used for lipoplex formation.
LIPOSOME
PREPARATION
LIPOSOME AMOUNT (μg) DNA (μg)
DOPE:Chol-T 7.11µg 10.665 14.22 1
DOPE:Chol-
T:PEG
8.79µg 13.185 17.58 1
DOPE:ChoL-
T:Sc-5
11.52µg 15.36 17.92 1
DOPE:Chol-
T:Sc-5:PEG
8.91µg 13.365 17.82 1
DOPE:Chol-
T:Sc-2
11.835µg 15.78 18.41 1
DOPE:Chol-
T:Sc-2:PEG.
9.12µg 13.68 18.24 1
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3.2.2.3 ETHIDIUM BROMIDE INTERCALATION ASSAY
This assay was conducted at an excitation wavelength of 520 nm and emission was monitored
at 600 nm using a GLOMAX multi+ detection system (Promega Biosystems, Sunnyvale,
USA). Briefly, 2 µl of stock ethidium bromide solution (1 mg/ml) was added to 100 µl of HBS
in 2 wells of a black 96 well plate and measured to obtain a baseline relative fluorescence of
0. Thereafter, 4.8 µl (1.2 µg) of pCMV-luc DNA was added to the mixture and the reading
taken was assumed to represent 100% relative fluorescence. Following this, 1 μl (2.37 μg)
aliquots of the liposome preparation was added stepwise to the above mixture and readings
were taken until a plateau had been reached. Accurate readings were assured by thoroughly
mixing samples to promote full dispersion of the liposome in the solution, thus encouraging
complete association with the DNA. Results obtained were plotted as relative fluorescence
percentages against mass of cationic liposome.
3.2.2.4 TRANSMISSION ELECTRON MICROSCOPY
Cationic liposome – DNA complexes were characterised using transmission electron
microscope. Cationic liposomes were diluted to a ratio of 1:5 with sterile HBS. Briefly, 2 µl
of the diluted liposome suspension was placed onto a Formvar coated copper grids. To this
was added 2 µl of 0.5% uranyl acetate and the excess liquid was blotted using filter paper. The
grids were allowed to dry for 2 minutes and immediately vitrified or plunged into liquid
propane at –183 °C.  The samples were then viewed in a high resolution transmission electron
microscope (JEOL1010). The electron micrographs were digitally captured using an Olympus
MegaView III camera and SIS iTEM software (Tokyo, Japan).
3.2.2.5 ZETA SIZING
Zeta sizing was carried out using the Malvern Zetasizer Nanoseries (Malvern Instruments,
Worcestershire, UK). All lipoplexes were diluted 1: 20 in HBS. Readings were measured in
the zetasizer at 25 C and data recorded using the Zetasizer software, version 6.30.
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3.2.2.6 STATISTICAL ANALYSIS
The particle sizes of lipoplexes were evaluated using the matched student t-test and the P-
values of < 0.05 were considered to be significant.
3.3 RESULTS AND DISCUSSION
3.3.1 GEL RETARDATION ASSAY
Gel retardation assay can also be termed as the electrophoretic mobility shift assay or the band
shift assay. This assay has been widely used to detect DNA binding proteins found in crude oil
extracts and also used for studying DNA- binding protein activity. This assay was originally
devised by Fried and Crothers (1981) when they were studying protein – DNA interaction
kinetics. In this assay the liposome-DNA complexes are expected to remain intact and migrate
slowly compared to free DNA which will freely enter the gel during agarose gel
electrophoresis.
When all DNA is liposome bound, creating an electroneutral complex, the DNA will not be
able to enter the gel and the complex will be viewed as an intense fluouresence band in the
well. Sometimes complexes float out of the well during electrophoresis and reduces the
fluorescence observed (Singh, 2005).
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Figure 3.3: Gel retardation assay of lipoplexes. Reaction mixtures (11 μl) comprised of a
constant amount of pCMV-luc DNA (0.5 μg) and varying amounts of cationic liposomes in HBS. Lane
1: naked DNA which serves as a control. Cationic liposome: DNA ratios (w/w) from lane 2-8 (1:1, 2:1,
3:1, 4:1, 5:1, 6:1, 7:1) were used for all six lipoplexes, viz. A: DOPE + Chol-T; B: DOPE + Chol-
T + PEG; C: DOPE + Chol-T + Sc-5; D: DOPE + Chol-T + Sc-5 + PEG; E: DOPE + Chol-T
+ Sc-2; F: DOPE + Chol-T + Sc2 + PEG.
43
Figure 3.3 (A-F) shows the binding abilities of the cationic liposomes to DNA. During agarose
gel electrophoresis the control naked DNA (lane 1), which is negatively charged, migrates
freely from the cathode (negative) to the anode (positive). Lane two to eight contained a
constant amount of plasmid DNA (0.5 μg) mixed with varying amounts of liposomes. From
the results, the control displayed all three DNA conformations after electrophoresis. The band
closest to the well was the nicked DNA, followed by the linearised DNA and the supercoiled
DNA which moved furthest away from the well towards the anode. In Figure 3.3 (A, B, D and
F), complete retardation of DNA was observed at DNA: cationic liposome charge ratios of 1:2,
whereas in Figures 3.3 (C and E) complete retardation of DNA was observed at DNA: cationic
liposome charge ratios of 1:3. Table 3.2 shows the end point ratios of the six liposome
formulations.
Table 3.3: Cationic liposome to plasmid DNA charge and mass ratios at complete retardation
(end point ratios).
LIPOSOME CHARGE RATIO (+/-) MASS RATIO (w/w)
DOPE:Chol-T 2:1 7.11: 1
DOPE:Chol-T:PEG 2:1 8.79 : 1
DOPE:Chol-T:Sc-5 3:1 11.52: 1
DOPE:Chol-T:Sc-5:PEG 2:1 8.91 : 1
DOPE:Chol-T:Sc-2 3:1 11.835 : 1
DOPE:Chol-T:Sc-2:PEG. 2:1 9.12 : 1
Overall, good nucleic acid condensation abilities is a prerequisite for all gene delivery vectors
in gene therapy. The results above show that the cationic liposomes were capable of binding
and condensing DNA successfully.
3.3.2 NUCLEASE PROTECTION ASSAY
One of the problems that have been encounted in gene therapy studies, which has led to the
use of the vectors is the possibility of degradation of naked DNA by serum nucleases upon
entry into the cytoplasm of the target cells or organs. The nuclease protection assay was carried
out to determine the ability of the cationic liposomes to protect the integrity of the nucleic acid
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cargo. In this study, serum nucleases were used to perform the protection assays. Nucleases
are enzymes that have the ability to cleave the DNA phosphodiester bonds leading to their
degradation.  Figure 3.4 A-C shows the nuclease protection ability of the six liposome
formulations.
Figure 3.4: Nuclease protection assay of cationic liposome/DNA complexes. Complexes were
incubated in the presence of 10 % serum. In all gels, lane 1 contained undigested plasmid DNA,
lane 2 contained plasmid DNA treated with serum and Lane 3-8 contained the different
lipoplexes incubated with serum.
A: lane 3-5 DOPE + Chol-T, lane 6-8 DOPE + Chol-T + PEG
B: lane 3-5 DOPE + Chol-T + Sc-5, lane 6-8 DOPE + Chol-T + Sc-5 + PEG
C: lane 3-5 DOPE + Chol-T + Sc-2, lane 6-8 DOPE + Chol-T + Sc2 + PEG
In this assay, lipoplexes were prepared as described in section 3.2.2.2.The lipoplexes may play
a role in the reduction of the electrostatic repulsion forces between the cell surface and the
DNA while also protecting the DNA from being degraded by enzymes such as nucleases within
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cytoplasm or serum. From the results above one can observe that the control DNA (lane 1)
showed all three forms of DNA which are nicked, linear and supercoiled. However, when the
same DNA was treated with serum (lane 2) no DNA bands were observed after gel
electrophoresis. A smear in lane 2 was seen in all three figures which is indicative of the
degradation of DNA by the enzyme. In the case of the lipoplexes that were treated with serum
(lanes 3-8), all three forms of the DNA were observed, although the fluorescence of
supercoiled DNA band  in Figures 3.4 B and C is very light. This indicates that some of the
supercoiled forms may have been nicked by the nucleases to produce the closed circular forms.
The use of SDS assisted in the release of the DNA from the respective lipoplexes and hence
we were able to visualise the DNA band on the gel. Overall, all liposomes have shown that
they are able to bind and protect the integrity of the DNA cargo.
3.3.3 ETHIDIUM BROMIDE INTERCALATION ASSAY
Ethidium bromide is known as the dye that strongly interacts with the double helix of DNA by
intercalation. The ethidium bromide intercalation assay is widely employed to assess the
strength of the interaction between the plasmid DNA and the cationic liposome. The
intercalation of ethidium bromide between the helical strands of DNA can be observed through
fluorescence emission. In this study, plasmid DNA was treated with ethidium bromide
followed by the addition of the respective cationic liposomes. Figure 3.5 A-C show relative
fluorescence as percentages against various amounts of liposome.
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Figure 3.5 Ethidium bromide intercalation assay. Cationic liposomes were added to plasmid
pCMV-luc DNA (0.5 µg) pre-treated with ethidium bromide dye. Arrows indicate the point of
inflection.
A: DOPE + CHOL-T, and DOPE + CHOL-T + PEG
B: DOPE + CHOL-T + Sc-5, and DOPE + CHOL-T + Sc-5 + PEG
C: DOPE + CHOL-T + Sc-2, and DOPE + CHOL-T + Sc2 + PEG
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The ethidium bromide fluorescence is known to be greatly increased or enhanced through its
intercalation into the double stranded DNA. However, ethidium bromide fluorescence could
be reduced or quenched by the addition of the cationic liposomes which should electrostically
bind to the DNA. From the results one can observe (Figure 3.5) that upon sequential addition
of each cationic liposome to the plasmid DNA/ethidium bromide/HBS complex, there was a
steady decrease in the fluorescence intensity. This confirms that as the cationic liposomes were
added, they gradually electrostatically interacted with and bound to the plasmid DNA thereby
displacing the intercalated ethidium bromide. There was a slight difference between the non-
PEGylated cationic liposomes and those that were PEGylated in that the relative fluorescence
decreased about 30-40 % for all the non PEGylated cationic liposomes, compared to about
50% (point of inflection) for the PEGylated cationic liposomes. Also, the PEGylated cationic
liposomes reached the plateau faster or sooner than the non-PEGylated liposomes. This
difference in final relative fluorescences suggest that the non-PEGylated liposomes compact
DNA much better than do the PEGylated liposomes.
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3.3.4 TRANSMISSION ELECTRON MICROSCOPY AND ZETA-SIZING
Figure 3.6 A-F show the TEM images for the lipoplexes at the optimum binding ratios.
Figure 3.6 Transmission electron micrographs of lipoplexes formed between cationic
liposomes and plasmid DNA. A: DOPE + CHOL-T; B: DOPE + CHOL-T + PEG; C: DOPE
+ CHOL-T + Sc-5; D: DOPE + CHOL-T + Sc-5 + PEG; E: DOPE + CHOL-T + Sc-2; F:
DOPE + CHOL-T + Sc2 + PEG. Bar = 100nm
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Cryo-transmission electron microscopy was used to characterise the lipoplexes formed
between the DNA and the cationic liposomes. The images (Figure 3.6 A-F) obtained revealed
different morphological characteristics of these lipoplexes at optimum binding ratios, such as
average diameters and sizes. As seen in Table 3.4, the hydrodynamic diameter of the lipoplexes
as determined from zeta-sizing, ranged from 96.7 nm for the un-PEGylated, targeted lipoplex
to 193.5 nm for the unPEGylated and untargeted cationic liposome.
Table 3.4: Zeta sizes of different cationic liposomes-plasmid DNA lipoplexes. Data are










The PDI values ranged from 0.193 to 0.708 suggesting that most of the lipoplexes were
polydispersed. However, PDI values closer to 0.1 would indicate a more monodisperse
population of lipoplexes. From the images it can be noted that the lipoplexes formed had
roughly spherical shapes but differed from one to the other, especially the lipoplexes that were
not PEGylated, produced vastly different images and shapes of ipoplexes compared to those
that contained PEG. Lipoplexes seemed to appear in the form of clusters of small vesicles.
This is particularly true for the PEGylated lipoplexes. Lipoplex sizes are extremely important
as those with smaller average sizes may accumulate more easily in the vesicles during uptake
compared to larger lipoplexes. Furthermore, it will influence their ability to enter specific cells
or tissues with smaller pore sizes eg. in the liver. The diameter of these vesicles is
approximately in the 100-200 nm range. Hence, it will be expected that the smaller sized pores
in liver tissue will favour the uptake of these smaller lipoplexes than larger lipoplexes
(Saffarian et al., 2009).
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CHAPTER FOUR
4. IN VITRO CYTOTOXICITY AND TRANSFECTION   STUDIES
4.1 INTRODUCTION
Cytotoxicity is a measure of the degree or level of toxicity of a specific compound to cells.
Cells may respond in a variety of ways after being exposed to certain compounds or assemblies
such as liposomes. There are different outcomes that may be seen after exposure, such as
necrosis, where cells lose the integrity of the cell membrane and die due to cell lysis, or
alternatively the cells may stop growing or dividing due to activation of programmed cell
death, called apoptosis. Necrosis can be generally seen as swelling, loss of membrane integrity
and non-functioning of the cells.  Apoptosis on the other hand is due to well-defined
cytological and molecular events, which can also be linked to cytoplasmic shrinkage and DNA
cleavage. There are several assays available commercially which can be used to determine the
degree of toxicity of a specific compound to cells. These assays enable scientists to predict the
compounds and the dosage of the compound which will be safe for use in humans. Some
researchers employ these assays in order to understand normal and abnormal processes which
control cellular metabolism. Two of the most commonly used assays include the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide ) or the similar MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), cell viability
assays (Berridge et al., 2005).
Transfection is a technique used to study the functions of genes and gene products by inhibiting
or enhancing specific gene expression within the cell. Transfection methods can be classified
into three different groups viz. biological, chemical and physical. (Kim and Berwine, 2010).
Transfection methods enable scientists to deliver genes and other nucleic acids to a specific
target organ, tissue or cell. A new way to study genes and their products combining mRNA
and point directed transfection has also been proposed. Transfection alters or modifies the
overall functions of a cell. The exogenous genetic materials which has been introduced into
the cell can exist in one of the two different states, depending on it nature, leading to either
stable or transient transfection. In order to obtain stable transfection, one needs to introduce
genes / genetic material which have markers necessary for selection (transgenes) which are
integrated into the genome of the host cell, thereby sustaining gene expression even after
completion of host cells replication. However, transient transfected genetic material can be
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expressed for a certain period of time and here the exogenous DNA is not integrated into the
host genome (Kim and Berwine, 2010). One of the disadvantages associated with transient
transfected genes is that they may be lost during cellular division.
Reporter gene assays have been commonly employed to determine transfection activity. A
reporter gene produces a specific phenotype during transfection, which enables researchers to
differentiate between transformed cells (cells containing gene of interest) from those that are
not transformed. This selection of transformed cells from many of those that are not
transformed would otherwise be difficult if the reporter gene was not employed. Reporter
genes are known to express specific protein products which can be detected and quantified
easily in the laboratory. Reporter genes afford measurable activity at the transcription level on
elements which are contained within a promoter region of a gene.  These are DNA sequences
that are associated with the genes coding region which regulate gene transcription and are often
termed enhancers. To alter expression of the gene, transcription factors activate or suppress
the promoters. During the reporter gene assays, promoters are engineered into a plasmid
thereby enabling one to assess the activity at the transcription level through the expression of
the reporter gene. The ideal reporter gene must have the following features; it must not be toxic
to target cells, it must be easily quantifiable, it should have high ratios of signal-to-noise or
low endogenous background, gene product must be resistant to chemicals which are used for
processing of the product, and finally, the assay itself must be reliable and sensitive.
One of the most commonly used reporter genes is the firefly luciferase gene. This gene was
isolated from the North American firefly Photinus pyralis. This organism expresses the
luciferase enzyme which permits it to glow in the dark. The enzyme luciferase catalyzes the
following reaction (Ignowski and Schaffer, 2004).
Luciferen    +     O2 +    ATP
Oxyluciferin + CO2 +   AMP   +   PPi     +     LIGHT
Luciferase
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4.2 MATERIALS AND METHODS
4.2.1 MATERIALS
The HEK293 cell line was obtained from the Anti-Viral Gene Therapy Unit, Medical School,
University of the Witwatersrand, and the HepG2 cell line and dimethylsulfoxide (DMSO) were
purchased from Highveld Biological (PTY) LTD, Lyndhurst, South Africa. Luciferase Assay
Kit (Luciferase Assay reagent and Cell Culture Lysis reagent) was purchased from Promega
Corporation (Madison, USA). Bicinchoninic acid (BCA) assay reagent and asialofetuin were
purchased from Sigma-Aldrich Co (St. Louis, USA). Eagles Minimal Essential Medium
(EMEM) and Foetal Bovine Serum (FBS) were purchased from Lonza Bio-Whittaker,
Walkersville, USA. Phosphate buffered saline (PBS) tablets and 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) salt were purchased from Merck (Darmstadt,
Germany). Tissue culture plastic wares were all obtained from Corning Incorporated (New
York, USA).  All other reagents were of analytical grade.
4.2.2                METHODS
4.2.2.1. GROWTH AND MAINTENANCE OF CELLS
Maintenance of cells and cell culture assays were carried out in a Class II Biosafety cabinet
which ensured sterility and prevention of contamination. Cells were frequently observed for
growth using a Nikon TMS inverted light microscope (100 x magnification) (Nikon
Corporation, Tokyo, Japan).  Complete medium (EMEM + 10% FBS + 100 µg / ml penicillin,
100 µg/ ml streptomycin) was routinely changed to ensure cell growth. Sub-culturing and
cryopreservation of cells was carried out when cells were in a semi-confluent / confluent state.
4.2.2.2 RECONSTITUTION OF CELLS
Previously cryopreserved cells were removed from the biofreezer and immediately placed in a
37 °C waterbath to thaw. Thereafter, the vial was wiped with ethanol and under sterile conditions,
the cell suspension was transferred to a sterile microcentrifuge tube and centrifuged at 3000 rpm for 1
min. The supernatant containing the DMSO was then discarded and the pellet were
reconstituted in 1 ml of fresh complete medium. This was then transferred to a tissue culture
flask containing 4 ml of complete medium. Flasks were incubated in a Steri-cult CO2 incubator
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HEPA Class 100 (Thermo-Electron Corporation, Waltham, Massachusetts, USA) at a
temperature of 37 °C. Medium was routinely changed every 2-3 days using standard aseptic
techniques and cells were monitored regularly until they reached confluency.
4.2.2.3 TRYPSINIZATION
When the cells had reached confluency, the old medium was removed from the flask, and cells
were washed with 5 ml of sterile Phosphate Buffered Saline (PBS) (150 mM NaCl, 2.7 mM
KCl, 1 mM KH2PO4, 6 mM Na2HPO4; pH 7.5). Thereafter, 1 ml of a trypsin/versene mixture
was introduced to the cells for the trypsinization process. Cells were observed for rounding off
using the Nikon TMS inverted microscope. The process of trypsinization generally took about
3-5 minutes at 37 °C. Thereafter, 2 ml of complete medium was added to the flask containing
cells and the flask was tapped gently against the palm of the hand in order to dislodge cells.
Cells were then split as desired into 25 cm2 flasks or plated for assay purposes into a 48-well
plate. The cells were then incubated at 37 ° C and medium was changed every 2-3 days using
aseptic techniques. Once cells had reached confluency, they were either trypsinized again or
plated for assay puposes or cryopreserved either in a -80   biofreezer (Nuaire, Lasec Laboratory
and Scientific Equipment) for short term or in liquid nitrogen for long term storage.
4.2.2.4 CRYOPRESERVATION OF CELLS
Cells at or close to confluency were trypsinized as in 4.2.2.3. Cells were then pelleted by
centrifugation at 1000 rpm for 3 minutes and the pellet re-suspended in 0.9 ml of complete
medium and 0.1 ml of dimethylsulfoxide (DMSO). The cell suspension was briefly vortexed
and 1 ml aliquots of the cell suspension were transferred into 2 ml cryovials, which were then
placed into a Nalgene Mr. Frosty 1C freezing container containing isopropanol and stored in
the -80 °C biofreezer overnight. Thereafter, the vials were transferred to cryo-boxes and kept
in the biofreezer or placed in liquid nitrogen.
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4.2.2.5 CYTOTOXICITY STUDIES
Cytotoxicity of liposomes was measured using the MTT cell viability assay. HepG2 and
HEK293 cells were trypsinized and seeded into 48 well plates at a seeding density of 1.5 x 105
cells per well. Cells were then incubated at 37 °C overnight (24 hours). Lipoplexes were
prepared as described in Chapter 3 section 3.2.2.2. Then lipoplexes were incubated for 30
minutes at room temperature. Spent medium was removed from cells and replaced with 0.3 ml
of complete medium (EMEM + 10% FBS + 100 µg / ml penicillin, 100 µg/ ml streptomycin).
This was followed by addition of the lipoplexes to the cells and incubation at 37 °C for 48
hours. Positive controls were set up using only cells with no lipoplexes added. The assay was
carried out in triplicate. After incubation, the medium was removed and cells were washed
with 300 µl PBS. Thereafter, 300 µl of MTT solution (5 mg/ml in PBS) and 0.3 ml medium
were added to each well containing cells and this was incubated for a further 4 hours at       37
°C. After the incubation period, the MTT solution and medium were removed and replaced
with 300 µl of dimethylsulfoxide (DMSO). Absorbance of the solubilized DMSO formazan
extracts were measured using a Mindray-MR-96A microplate reader (Vacutec, Hamburg,
Germany) at a wavelength of 570 nm.
4.2.2.6. TRANSFECTION STUDIES
HepG2 and HEK293 cells were trypsinized and seeded in 48 well plates at a seeding density
of 1.5 x 105 cells per well. Cells were then incubated in a 37 °C incubator overnight Lipoplexes
were prepared as in Chapter 3 section 3.2.2.2. and at the same ratios added for cytotoxicity
(4.2.2.5). Then lipoplexes were incubated for 30 minutes at room temperature. Spent medium
was removed from cells and replaced with 0.3 ml of complete medium. This was followed by
addition of the lipoplexes to the cells, and incubation at 37 °C for 48 hours. Two sets of controls
were set up viz; one containing only cells and a second containing cells with naked plasmid
pCMV-luc DNA (0.5 µg). The assay was carried out in triplicate. After incubation period, cells
were assayed for luciferase activity (section 4.2.2.6.2).
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4.2.2.6.1 COMPETITION ASSAY
The competition assay was carried out only on the targeted HepG2 cell line at the same cell
density and following the same protocol as in section 4.2.2.6. for the transfection.  The only
difference was that cells were first pre-incubated with asialofetuin (200 µg/well) for 30 minutes
prior to the addition of the lipoplexes. After the 48 hour incubation, the cells were assayed for
luciferase activity (section 4.2.2.6.2).
4.2.2.6.2 LUCIFERASE ASSAY
The Promega Luciferase Assay kit was used to measure the luciferase activity of the cells.  A
1x cell culture lysis reagent was prepared from a 5x lysis reagent stock (25 mM tris-phosphate,
pH 7.8; 2 mM dithiothreitol, 2 mM 1, 2-diaminocyclohexane – N, N, N’N’- tetra-acetic acid,
10% (v/v) glycerol, 1% (v/v) triton X-100) using 18 Mohm water.  Cells were prepared by
removing the old medium, and washing the cells with PBS (2 x 100 µl). Thereafter,
approximately 80 µl of 1x cell lysis reagent was added to the cells. The multiwell plate was
then placed on a STR 6 (Stuart Scientific, Staffordshire, UK) platform rocker for 15 minutes
at 30 rev/min. The cells were then scraped from the wells and the cell suspension transferred
into clean microcentrifuge tubes and microfuged at 12 000 x g for 5 seconds.   The supernatants
or cell free extracts were then used for the determination of luciferase activity. Briefly,
luciferase assay reagent (100 µl) was added to 20 µl of supernatant at room temperature,
followed by mixing and reading of luminescence (relative light units) in a GloMax®-Multi
Detection System (Promega BioSystems, Sunnyvale, USA) operated by Instinct software.
Protein concentration of the cell free extracts were assessed using the bicinchoninic acid
colorimetric (BCA) assay determined colorimetrically at 562 nm, as per manufacturer’s
protocol. The luminescence readings in relative light units (RLU) were normalised against the
the protein concentrations and was expressed as RLU/mg protein.
4.2.2.7 STATISTICAL ANALYSIS
Graph pad prism version 5.04 (GraphPad Software Inc, USA) was used to perform the statistical
analysis of the results using the student t-test. P < 0.05 was considered to be significant.
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4.3 RESULTS AND DISCUSSION
4.3.1 GROWTH AND MAINTENANCE OF CELLS
Both cell lines were successfully propagated in complete medium (EMEM + 10% FBS + 100
µg / ml penicillin, 100 µg/ ml streptomycin) in the laboratory. The complete medium used is
one of the many examples of growth medium which have been formulated to support the
growth of cells in cell culture laboratories. The EMEM contains essential amino acids, salts,
glucose and vitamins. Amino acids are compulsory requirements for all cell culture media
because they are the building blocks of proteins and are needed for cell proliferation. Since
cells cannot synthesize all the amino acids, the essential ones are incorporated into the media.
Inorganic salts help in retention of the osmotic balance in the medium and also assists in
regulating the integrity of the cell membranes. Glucose provides cells with energy which is
necessary for growth. Vitamins are also important for the cell proliferation and are commonly
incorporated into the medium since cells cannot sufficiently synthesise their own (Arora,
2013).
Serum provides the necessary growth factors for the survival and growth of cells in the
medium. Serum has advantages and disadvantages when added to the medium. The advantages
of serum include providing hormones which stimulates cell function and growth, playing a
role in cell attachment and spreading, helping to maintain the pH of the medium and to assist
in minimising the damage to cells due to viscosity. However, serum may lack uniformity, may
contain factors which inhibit growth and could increase the risk of the medium contamination
which may lead to cell death.
The addition of antibiotics to the complete medium is important in controlling bacterial and
fungal growth. Antibiotics prevent contamination of medium which could result in death of
cells (Arora, 2013). Complete medium provided cells with all these essential nutrients
discussed above, thus enabling the cells to grow and proliferate. From our observation the
HEK293 cells grew and reached confluency quicker than the HepG2 cells. Once confluency
was reached, cells were trypsinized using trypsin-versene solution, which contains the enzyme
trypsin for detaching the cells and versene or ethylenediamine tetracetic acid (EDTA) for the
chelation of the divalent cations such as calcium and magnesium and to increase the activity
of the enzyme allowing it to hydrolyse the necessary peptide bonds.
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4.3.2 CYTOTOXICITY STUDIES
Some compounds or delivery agents may be toxic to the target organ, cell or tissue and hence
not suitable for gene or drug delivery. Hence, it is essential that the compound or vector be
assessed for its cytotoxity levels in vitro. One method which is commonly used to determine
the toxicity of compounds is the MTT cell viability assay. This assay was first described by
Mosmann (1983) and is based on mitochondrial activity and integrity which will only be
present in viable cells (van Meerloo et al., 2011). The MTT-[3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyl-tetrazolium bromide] dye is membrane permeable, and during this assay the dye
interacts with the cells and the mitochondrial succinate dehydrogenases metabolizes the MTT
to produce dark-purple/blue crystals of formazan as shown in Figure 4.1. These crystals
generally accumulate in cells which are not damaged and are proliferating. Hence the quantity
of formazan produced is directly proportional to the number of viable cells. These formazan
crystals are then dissolved in an appropriate solvent (e.g. DMSO) and the optical density at
570 nm is determined colorimetrically and correlated with cell viability assuming 100%
viability of untreated cells.
Figure 4.1: Metabolism of MTT-dye (yellow) to MTT-formazan crystals (blue) by
mitochondrial dehydrogenases (mDH) of living cells: Adapted from http://www.uni-
giessen.de/cms/fbz/fsp/meu/methods/analysis2/cell-proliferation [Accessed 03 July 2014].
The cytotoxicity assay was done in order to assess the toxicity of the cationic liposomes to
both HepG2 and HEK293 cell lines. Figures 4.2, 4.3 and 4.4 depicts the levels of cytotoxicity
achieved for the six liposomal formulations in the two cell lines. From the graphs it can be
seen that these lipoplexes were reasonably well tolerated by the cells, with the HEK293 cells
showing greater overall cell survival than the HepG2 cells. Overall, in the HEK293 cells,  cell
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survival ranged from around 60% for the Chol-T + Sc-5 + PEG liposomes at liposome:DNA
charge ratio of 4:1 (Figure 4.3B) to well over 90% for the untargeted Chol-T, Chol-T+ PEG
and the Chol-T +Sc2 + PEG liposomes (Figures 4.2A,B,and 4.4B) at a liposome:DNA charge
ratio of 2:1.  However in the HepG2 cells, cell survival ranged from just over 50% for the
Chol-T+Sc2+PEG liposome (3:1) (Figure 4.4A) to over 80% for the Chol-T (charge ratio 2:1),
Chol-T+PEG (charge ratio 4:1), Chol-T +Sc5 (charge ratio 4:1), Chol-T +Sc5 + PEG (charge
ratio 3:1), and Chol-T +Sc2 + PEG (charge ratio 2:1) (Figures 4.2 A-B, 4.3A-B and 4.4B).
Generally, it could be seen that the control untargeted liposomes (Chol-T and Chol-T+PEG)
(Figure 4.2A-B) were least toxic to both cell lines when compared to the liposome formulations
that contain the targeting ligands Sc2 and Sc5 (Figures 4.3A-B and 4.4A-B). The highest cell
death recorded for the control liposomes was 30% for Chol-T+PEG (charge ratio 2:1) in the
HepG2 cells. Furthermore, the HEK293 cells all showed cell survival over 80% for these
liposomes.
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Figure 4.2: Cytotoxicity studies of lipoplexes in HEK293 and HepG2 cell lines in vitro.
Varying amounts of cationic liposomes were added to a constant amount of DNA (Table 3.2).
Data are presented as means ±S.D. (n = 3). There were significant differences between test and
control results. * P<0.05, ***P< 0.001.
(A) DOPE + Chol-T): pCMV-Luc DNA












































Figure 4.3: Cytotoxicity studies of lipoplexes in HEK293 and HepG2 cell lines in vitro.
Varying amounts of cationic liposomes were added to a constant amount of DNA (Table 3.2).
Data are presented as means ±S.D. (n = 3). There were significant differences between test and
control results. * P<0.05, ***P< 0.001.
(A) DOPE + Chol-T + Sc-5): pCMV-Luc DNA













































Figure 4.4: Cytotoxicity studies of lipoplexes in HEK293 and HepG2 cell lines in vitro.
Varying amounts of cationic liposomes were added to a constant amount of DNA (Table 3.2).
Data are presented as means ±S.D. (n = 3). There were significant differences between test and
control results. * P<0.05, ***P< 0.001.
(A) DOPE + Chol-T + Sc-2): pCMV-Luc DNA
















































In the case of the ligand containing formulations, there was no significant differences in
toxicity levels for the acetylated and non-acetylated formulations. Also, significant to note was
that the targeted PEGylated liposomes (Figures 4.3B and 4.4B) seemed to be better tolerated
by the cells than their non-PEGylated counterparts, with the exception of Chol-T+Sc5 +PEG
at charge ration of 4:1 (Figure 4.3B) where the cell survival is much lower. The results reveal
that the toxicity is liposome-dependent and with an increase in the amount of liposome or N/P
charge ratios (+/-), the more toxic the cationic liposomes are. The findings of this study are in
agreement with the study performed by Romoren et al (2005), where incorporation of DOPE
increased the liposomes toxicity with the toxicity dependent on the N/P charge ratios (+/-).
According to Romoren et al. (2004), the pH-sensitive DOPE which is incorporated in the
cationic liposomes contribute to the toxicity of liposomes. Lysosomes tend to degrade most
complexes during transfection, however since cationic liposomes form the hexagonal phase at
acidic pH (pH associated with lysosomes), DOPE may enhance the cationic liposomes toxicity
by destabilizing the membrane of a liposome (Romoren et al., 2004). Results show that non-
acetylated Sc-5 cationic liposomes are less toxic to cells than the acetylated counterpart; these
findings are in agreement with previously published articles on mammalian cells. The
PEGylated Chol-T and DOPE liposome shows more toxicity to cells compared to the non-
PEGylated DOPE and Chol-T liposome, which corroborate findings by Romoren et al., 2004.
However, in the presence of a target ligand such as Sc-2, PEGyaltion is seen to be less toxic
to cells compared to its non-PEGylated counterpart.  The results show that even though the
cationic liposomes were toxic to cell, the cell viability was above 60% at most charge ratios,
which indicate that the cationic liposomes were reasonably well tolerated by both cell lines.
4.3.3 TRANSFECTION STUDIES
Transfection is the method of introducing genetic material such as nucleic acids into the cells
in order to alter their genetic function and trait. Prepared cationic liposomes were used to
deliver the plasmid pCMV-luc DNA into the receptor negative HEK293 and receptor positive
HepG2 cell lines in vitro. Cationic liposomes contain phospholipids, which are building blocks
of cellular membranes. The structure of a cationic cytofectin is known to possess a positively
charged or cationic head group and hydrocarbon or sterol chains. Charged head groups on the
cationic liposomes facilitate the interaction of the lipid with the negatively charged phosphate
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backbone of the nucleic acids. The cationic lipid, Chol-T (Figure 2.3A) used in this study to
deliver plasmid DNA had a positive surface charge which facilitated the electrostatic
interaction of the liposome membrane and the plasmid DNA. The complexes thus formed are
then taken up by cells through the process of endocytosis which could be receptor mediated in
the presence of an appropriate ligand.
Transfection activity was determined using the luciferase reporter gene assay. This assay is
commonly used in laboratories to study the expression of genes at the level of transcription
and is convenient to perform. The luciferase enzyme that is expressed allows the organism to
emit light, a process termed as bioluminescence. The reporter gene that was employed during
transfection was the firefly luciferase gene. The study is based on the fact that the transfected
cells will emit light or bioluminescence which is measured in a luminometer and expressed as
relative light units of luciferase activity as shown in Figures 4.5, 4.6 and 4.7.
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Figure 4.5: Transfection studies of lipoplexes in HEK293 and HepG2 cell lines. Varying
amounts of cationic liposomes were added to pCMV-luc plasmid DNA (0.5 µg) in HBS (final
volume 10 µl) to achieve +/- charge ratios as indicated A: DOPE + Chol-T and            B: DOPE
+ Chol-T + PEG. Data are presented as means ±S.D. (n = 3). There were significant differences






























































Figure 4.6: Transfection studies of targeted lipoplexes in HEK293 and HepG2 cell lines.
Varying amounts of cationic liposomes were added to pCMV-luc plasmid DNA (0.5 µg) in
HBS (final volume 10 µl) to achieve +/- charge ratios as indicated A: DOPE + Chol-T + Sc-5
and B: DOPE + Chol-T + Sc-5 + PEG. Data are presented as means ±S.D. (n = 3). There were































































Figure 4.7: Transfection studies of targeted lipoplexes in HEK293 and HepG2 cell lines.
Varying amounts of cationic liposomes were added to pCMV-luc plasmid DNA (0.5 µg) in
HBS (final volume 10 µl) to achieve +/- charge ratios as indicated A: DOPE + Chol-T + Sc-2
and B: DOPE + Chol-T + Sc2 + PEG. Data are presented as means ±S.D. (n = 3). There were































































The luciferase reporter gene was used to quantitatively assess the in vitro transfection
efficiencies of the lipoplexes in HEK293 cells which lack the asialoglycoprotein receptor
(ASGP-R) and HepG2 cells which are ASGP-R-positive. Furthermore, this study also served
to determine whether the acetylation on the hydroxyl groups of the galacto-compounds had an
effect on the ability of the targeted lipoplexes, in which they are incorporated, to bind the
ASGP-R and enter the cell through receptor-mediated endocytosis, thereby enhancing
transfection. The effect of PEGylation of the liposomes on the overall transfection activity was
also examined.
Figures (4.5, 4.6 and 4.7) shows transfection activity of the six lipoplex formulations at the
various charge ratios. Luciferase activity is reflected as relative light unit (RLU) per mg soluble
protein. All liposomes showed successful transfection in both cell lines. The degree of
luciferase activity is compared to that of the two controls which show almost no luminescence.
From the two control untargeted liposomes the PEGylated lipoplex (Figure 4.5 B) produced
greater  luciferase activity of around 3.1 x 106 RLU/mg protein for the HepG2 cells and over
2.5 x 10 RLU/mg protein for the HEK293 cells at the charge ratio of 4:1. Results also show
that the HepG2 cells produced higher luciferase activity at all charge ratios compared to the
HEK293 cells, although HEK293 cells are generally regarded as easy to grow and transfect
readily compared to the HepG2 cells.
For targeted lipoplexes (Sc5 with and without PEG) (Figure 4.6 A-B) the transfection activity
was lower that the untargeted control lipoplexes (Figure 4.5 A-B) in both cell lines. Here again
the HEK293 cells showed lower transgene activity with  maximum activity at a charge ratio
of 5:1 (1x106 RLU/mg) and lowest luciferase activity at a charge ratio of 3:1 (5 x105 RLU/mg)
in the non-PEGylated lipoplex. In contrast the HepG2 cells produced higher transfection
activity at a charge ratio of 3:1 (2x106 RLU/mg) (Figure 4.6 A). However, the targeted
PEGylated complexes produced increased transfection activity especially in HepG2 cells,
notably at charge ratio of 3:1, where luciferase activity was above 5x106 RLU/mg protein
(Figure 4.6 B) compared to the low levels seen again for the HEK293 cells.
For the acetylated targeted lipoplexes (Figure 4.7 A-B) the HEK293 cells displayed better
transfection activity than the HepG2 cells with the highest transfection level recorded at a
charge ratio of 5:1 (1x106 RLU/mg) in the non-PEGylated lipoplex(Figure 4.7 A). Results
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show that the PEGylated lipoplexes (Figure 4.7 B) produced lower transfection activity in both
cell lines with the exception of lipoplexs at a charge ratio of 2:1 which produced luciferase
activity above 2x106 RLU/mg protein in the HepG2 cells only.
From the results presented in (Figures 4.5, 4.6 and 4.7), it may be concluded that acetylation
and PEGylation affect the ability of the the lipoplexes to transfect cells. De-acetylated cationic
liposomes (Sc5 – Figure 4.6) showed higher luciferase activities compared to the acetylated
cationic liposomes (Sc2- Figure 4.7). PEGylation was shown to enhance the transfection
activities in HepG2 cells but not in the HEK293 cells. The enhanced transfection efficiencies
which are observed when PEG is incorporated in cationic liposomes could be due to the fact
that the sizes of lipoplexes which were formed between PEGylated cationic liposomes and
plasmid DNA were smaller. It is also important to note that the clathrin coated pits, which are
the portals for cell entry by receptor mediated endocytosis, are <200 nm in diameter (Saffarian
et al., 2009), therefore the smaller targeted PEGylated lipoplexes would gain entry into cells
more easily. The acetyl groups on the 2’, 3’, and 4’positions may cause steric problems making
it difficult for the ASGP-R binding site to accommodate the acetylated galactose moiety.
According to Lee (1982), for successful binding of the galactose compound to the ASGP-R,
the 2-OH (equatorial) and the 3-OH (equatorial) are both needed for binding, but the 4-OH
must be in the axial position and the –CH2OCH at C-5 can be modified. Binding is also
dependent on pH and Ca2+. Therefore modifying the galacto moiety by introducing the acetyl
group on the hydroxyl group (3-OH and 2-OH) may lead to less recognition by the receptor
since these –OH groups are required for binding. Hence, this could result in reduced
transfection activity compared to that of the de-acetylated cationic liposomes that were used.




Figure 4.8 Competition transfection assays in HepG2 cells. Cells were pre-incubated with
asialofectuin (200 µg/well) for 30 minutes before addition of lipoplexes mixtures (Table 3.2).
A: DOPE + Chol-T + Sc-5 and B: DOPE + Chol-T + Sc-5 + PEG.  Data are presented as means
±S.D. (n = 3). There were significant differences between results in cell lines at individual +/-






























































Figure 4.9 Competition transfection assays in HepG2 cells. Cells were pre-incubated with
asialofectuin (200 µg/well) for 30 minutes before addition of lipoplexes mixtures (Table 3.2).
A: DOPE + Chol-T + Sc-2 and B: DOPE + Chol-T + Sc2 + PEG.  Data are presented as means
±S.D. (n = 3). There were significant differences between results in cell lines at individual +/-






























































Competition assays were performed to verify that targeted lipoplexes were indeed taken up by
the cells ASGP-R-mediated endocytosis process. Results presented in Figure 4.8 (A) showed
that at the optimal transfection ratio 3:1 the presence of an excess of the ASGP-R ligand
asialofetin effectively reduced the transfection activity by DOPE, Chol-T, Sc-5 lipoplexes.
This was also the case with PEGylated lipoplexes formulated with Sc-5 (Figure 4.8 B).
Competition assays conducted with Sc-2-containing lipoplexes (Figure 4.9 A-B) also produced
a sharp decrease (more than 80%) in transfection activity in the presence of excess
asialofectuin. Thses results are similar to those obtained by Singh and coworkers using the
galactose ligand and excess asialofetuin in the competition assay. A massive decrease of 90%
in luciferase activity was observed (Singh et al., 2007). Although results presented here show
that the galacto-containing lipoplexes achieved higher transfection activities than the
lipoplexes containing tetra acetylated galactose units, it appears that the latter lipoplexes also
gain entry into the HepG2 cells via ASGP-R-mediation.
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CONCLUSION
This study was done in order to assess the properties of the cationic liposomes which have
been prepared using the thin film hydration method. Stable liposome formulations were
achieved with the liposomal components and mole ratios selected for this study. Gel retardation
showed that both acetylated and non-acetylated liposomes formed lipoplexes with plasmid
pCMV-luc DNA. The plasmid DNA was relatively well protected from serum nuclease
degradation as shown by the nuclease protection assay. PEGylation appeared to generate
smaller lipoplexes, and the PEGylated lipoplexes carried DNA in a less condensed state as
evidenced by ethidium bromide displacement assays. The lipoplexes were relatively non-toxic
under the transfection conditions employed in both cell lines. The lipoplexes displaying the
ASGP-R ligand β-D-galactopyranose achieved transfection levels up to 250 percent greater
than those achieved by lipoplexes decorated with tetra-O-acetylgalactopyranose. PEGylation
was accompanied by an increase in transfection activity in HepG2 cells but not in HEK293
cells. This would support the notion that smaller PEGylated lipoplexes are more readily
accommodated in the restricted space within coated pits and that cellular uptake in HEK293
cells is perhaps coated pit-independent. The competition assays confirmed ASGP-R mediated
uptake of Sc-2 and Sc-5 lipoplexes although there is a clear preference for the non-acetylated
galactopyranosyl moiety. These liposomal formulations have the potential as future non-viral
gene delivery vehicles and with further optimisation can be tested in vivo. Future studies may
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